Skip to content

Biodesix, Inc. BDSX Additional Paid-In Capital

Additional Paid-In Capital at other companies

NeoGenomics logo
NeoGenomicsNEO
$1.28B+3.2%
Veracyte logo
VeracyteVCYT
$1.7B+2.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$1.6B+5.0%
Personalis, Inc. logo
Personalis, Inc.PSNL
$916.12M+18.5%
Guardant Health logo
Guardant HealthGH
$2.93B+18.5%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$2.95B+15.8%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s additional paid-in capital?
Biodesix, Inc. (BDSX) reported additional paid-in capital of $514.68M in Q1 2026.
How has Biodesix, Inc.'s additional paid-in capital changed year-over-year?
Biodesix, Inc.'s additional paid-in capital increased by 6.2% year-over-year, from $484.51M to $514.68M.
What is the long-term trend for Biodesix, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Biodesix, Inc.'s additional paid-in capital has grown at a 10.6% compound annual growth rate (CAGR), from $299.95M to $495.29M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.